KINGSINO(002548)2025-04-29 12:00Financial Performance - The company's revenue for Q1 2025 was ¥1,168,508,441.22, representing an increase of 11.22% compared to ¥1,050,632,449.52 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥25,777,884.97, an improvement of 50.48% from a loss of ¥52,055,103.26 in the previous year[5] - The net cash flow from operating activities was ¥36,446,459.90, a significant increase of 125.73% compared to a negative cash flow of ¥141,637,995.57 in the same period last year[5] - The company's basic and diluted earnings per share improved to -¥0.03, a 50.00% increase from -¥0.06 in the previous year[5] - The weighted average return on equity improved to -1.72%, up by 1.86% from -3.58% in the same period last year[5] - The net profit for the current period is -26,941,988.21, compared to -52,239,334.92 in the previous period, showing an improvement of approximately 48.5%[28] - Operating profit for the current period is -27,008,127.71, an improvement from -50,295,736.86 in the previous period, indicating a reduction in losses by about 46.3%[28] - The total comprehensive income for the current period is -26,677,408.21, compared to -52,257,814.92 in the previous period, showing an improvement of approximately 48.9%[28] Assets and Liabilities - Total assets increased to ¥5,519,337,486.54 from ¥5,410,486,028.67, reflecting a growth of about 2.0%[24] - Total liabilities rose to ¥3,942,980,508.04 from ¥3,807,451,641.96, indicating an increase of approximately 3.5%[24] - The company's total equity decreased to ¥1,576,356,978.50 from ¥1,603,034,386.71, a decline of about 1.7%[24] - The company reported a net loss of ¥1,403,286,422.34 in retained earnings, worsening from a loss of ¥1,377,508,537.37 in the previous period[24] - Short-term borrowings rose to ¥1,645,452,060.96 from ¥1,420,758,297.41, an increase of approximately 15.8%[24] Revenue and Costs - Total operating revenue for the current period reached ¥1,168,508,441.22, an increase from ¥1,050,632,449.52 in the previous period, representing a growth of approximately 11.2%[26] - Total operating costs amounted to ¥1,193,656,966.71, up from ¥1,088,048,105.17, indicating an increase of about 9.7%[26] - Total revenue from operating activities is 1,047,399,347.01, up from 976,440,715.52 in the previous period, reflecting an increase of approximately 7.3%[29] Cash Flow and Investments - The company's cash and cash equivalents at the end of the period were ¥401,696,133.56, compared to ¥337,807,207.23 at the beginning of the period, reflecting a growth of approximately 18.9%[22] - Cash received from the disposal of fixed assets increased by 87.07% compared to the previous year, due to higher cash inflows from the disposal of productive biological assets[13] - The company reported a total investment cash outflow of 30,643,348.17, down from 56,281,323.80 in the previous period, indicating a decrease of approximately 45.5%[30] Accounts Receivable and Inventory - Accounts receivable increased by 203.44% compared to the beginning of the period, primarily due to an increase in receivables from feed sales[9] - Accounts receivable increased significantly to ¥186,384,188.20 from ¥61,424,543.79, marking a rise of approximately 203.5%[22] - Inventory decreased to ¥656,451,465.59 from ¥711,449,781.87, showing a reduction of about 7.7%[22] Expenses - Selling expenses increased by 36.13% year-on-year, mainly due to higher feed sales leading to increased costs[10] - The company incurred research and development expenses of 11,524,731.03, down from 13,207,925.43, representing a decrease of about 12.8%[28] - The company’s total liabilities increased, with a significant portion attributed to interest expenses of 36,167,868.35, down from 39,430,208.22 in the previous period[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 47,520[18]